Flagship explainer
What drives TSCAN THERAPEUTICS, INC.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$130M | FY2025 |
| |
| Income before tax | −$130M | FY2025 |
|
| Operating income | −$136M | FY2025 |
|
| $10.3M | FY2025 |
| |
| Ending assets | $229M | FY2025 |
|
| Beginning assets | $371M | FY2024 |
|
| $123M | FY2025 |
| |
| $241M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001193125-26-089884